IGC Pharma (IGC) Equity Ratio (2011 - 2026)

IGC Pharma (IGC) has 16 years of Equity Ratio data on file, last reported at 0.67 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.67, down 7.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.67 (down 7.91% YoY), and the FY2026 annual result was 0.67, down 7.91% from the prior year.
• Equity Ratio declined to 0.67 in Q1 2026 per IGC's latest filing, from 0.76 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.92 in Q3 2022 and troughed at 0.67 in Q1 2026.
• A 5-year average of 0.8 and a median of 0.8 in 2023 frame the typical range for Equity Ratio.
• The sharpest annual moves came in 2024 and 2025: Equity Ratio declined 16.7% in 2024, then increased 16.74% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.91 in 2022, then dropped by 11.9% to 0.8 in 2023, then fell by 14.25% to 0.69 in 2024, then grew by 10.86% to 0.76 in 2025, then dropped by 12.81% to 0.67 in 2026.
• Business Quant data shows IGC's Equity Ratio at 0.67 in Q1 2026, 0.76 in Q4 2025, and 0.83 in Q3 2025.